Microsatellite stable colon cancer models with BRAF or KRAS mutations in Subgroups II and IV have shown responses to the combination of EGFR (cetuximab), MEK (trametinib), and/or RAF (regorafenib) inhibition, providing a strong hypothesis for further evaluation. Here, MAP2K7 is linked to malignant colon neoplasm.